SteriMax
SteriMax is a privately owned Canadian pharmaceutical company that develops, manufactures, and distributes sterile injectable and specialty medicines, supplying hospitals, pharmacies, wholesalers, and GPOs across Canada from its Oakville, Ontario facility.
- Company typePrivate
- Founded1994
- HeadquartersOakville, Canada
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What SteriMax does
SteriMax is a privately owned Canadian pharmaceutical company headquartered in Oakville, Ontario, that develops, manufactures, and distributes sterile injectable and specialty medicines. Founded in 1994 by pharmacist Mahen "Mike" Acharya and now led by his son Samir Acharya (President & CEO), the company operates a 45,000 sqft facility with in-house R&D and product development labs, Health Canada and FDA-approved quality control labs, and secondary packaging capabilities. Its portfolio of more than 50 products spans generic sterile injectables and branded specialty medicines across therapeutic areas including anesthetics, anti-infectives, cardiovascular, critical care, electrolytes, hormones, and oncology. The company supplies approximately 40 million doses annually from a single manufacturing site and serves Canadian hospitals, retail and specialty pharmacies, wholesalers and distributors, and national and regional hospital group purchasing organizations.
SteriMax's product strategy emphasizes ready-to-administer (RTU) convenience formats, room-temperature stability, and traceable 2D barcoded unit-of-use packaging, including the first Canadian room-temperature Fulvestrant pre-filled syringe (2025), Calcium Gluconate RTU bags with 24-month shelf life (2025), and Cisatracurium with a red safety warning ferrule aligned to ISMP and Health Canada best practices. Distribution combines direct enterprise sales, GPO contracts, wholesaler and specialty distributor partnerships, retail pharmacy banner relationships, and global export partners. Pricing follows transaction-based terms on NET 30 invoicing with a $500 minimum order threshold. The company also operates a Health Canada Tier 3 Exceptional Importation program to mitigate Canadian drug shortages, sourcing from both US-labelled and, more recently, Chinese-authorized supply.
Revenue is generated through one-time product sales across multiple customer verticals with no usage-based or subscription components; the business is internally financed by the Acharya family with no venture capital or private equity backing identified. The leadership team combines pharmaceutical operations (CSO Ritesh Acharya), commercial execution (CCO Edward Rajasingham, EVP Sales & Marketing Craig Potvin), and business development and licensing expertise (EVP Edward Morrison, EVP Innovation Hamed Ghanei), supporting ongoing portfolio expansion through organic launches and inbound licensing and acquisition activity.
SteriMax firmographics
Firmographics- Name
- SteriMax
- Legal name
- SteriMax Inc.
- Website
- https://sterimaxinc.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- SteriMax is a privately owned Canadian pharmaceutical company that develops, manufactures, and distributes sterile injectable and specialty medicines, supplying hospitals, pharmacies, wholesalers, and GPOs across Canada from its Oakville, Ontario facility.
- Ownership category
- akta.pro rank
SteriMax industry classification
Industry- Product category
- Generic Sterile Injectable Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Sterile Injectable Generics (HLAIABAC)
- akta.pro secondary industry
- Generic Hospital & Institutional Products (HLAIABAL)
Keywords
Where SteriMax is headquartered
LocationHeadquarters
- HQ city
- Oakville
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
SteriMax business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Generic Sterile Injectables: SteriMax generates revenue through the sale of generic sterile injectable products, including over 50 products across various therapeutic categories such as anesthetics, anti-infectives, cardiovascular, critical care, electrolytes, hormones, and oncology.
- Branded Specialty Medicines: Revenue from branded medicines that address unmet medical needs through new and novel therapies, including both new chemical entities and reformulations of existing molecules.
- Exceptional Importation (Tier 3): Importation of foreign-authorized medications to address critical Tier 3 drug shortages in Canada, providing essential medicines when supply is disrupted.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Annual | Standard Order Terms |
| Transaction based/ take rate | Annual | Special Product Ordering |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels5 records
SteriMax product offering
Product offeringCore offering
SteriMax develops, manufactures, and distributes generic sterile injectable pharmaceuticals and branded specialty medicines for Canadian hospitals, pharmacies, and healthcare systems. The company offers over 50 products across therapeutic categories including anesthetics, anti-infectives, cardiovascular, critical care, electrolytes, hormones, and oncology, including proprietary ready-to-administer formats with 2D barcoding for medication safety.
Product overview
SteriMax is a privately owned Canadian pharmaceutical company and one of Canada's largest providers of sterile injectables and specialty medicines. The company operates a diversified portfolio of over 50 products organized into two main categories: Generic Medicines (sterile injectables designed for hospital, clinic, community and specialty care settings) and Branded Medicines (new medicines addressing unmet clinical needs through innovation and market access). The portfolio includes essential sterile injectables across therapeutic areas including anti-infectives, cardiovascular, critical care, oncology, electrolytes, hormones, anesthesia, and nutritional supplements. SteriMax delivers medicines directly to hospitals, pharmacies, wholesalers, and distributors through an end-to-end operational model encompassing regulatory affairs, product development, quality assurance, supply chain, and distribution. Notable products include Octreotide Injection, Magnesium Sulfate Injection USP, Cisatracurium Besylate Injection, Calcium Gluconate Injection Bags (ready-to-administer format), Doxycycline for Injection (first approved in Canada), and Fulvestrant Injection (first room-temperature stable format). The company supplies approximately 40 million annual doses and employs 200 people at its Oakville, Ontario facility.
Differentiator
Problem solved
Functional benefit
Products and services
- Generic Sterile Injectables Portfolio SteriMax's core portfolio of over 50 generic sterile injectable medicines across therapeutic categories including anti-infectives, cardiovascular, critical care, electrolytes, hormones, oncology, and anesthesia, designed for hospital, clinic, community, and specialty care settings in Canada.
- Branded Specialty Medicines Branded medicines addressing unmet clinical needs through new and novel therapies, including new chemical entities and reformulations of existing molecules brought to the Canadian market through partnerships with global pharmaceutical companies.
- Tier 3 Exceptional Importation Service Importation of foreign-authorized medications to address critical Tier 3 drug shortages in Canada, providing essential medicines when domestic supply is disrupted.
- Calcium Gluconate in Sodium Chloride Injection Bags (Ready-to-Administer)
Quantifiable outcome
- 40 million annual doses of medication supplied
- +3 more outcomes
Companies that use SteriMax
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles4 records
SteriMax technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
SteriMax partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- GFL Environmental Services Inc.minorGFL Environmental Services Inc. handles expired product returns processing for SteriMax. Customers return expired products within 12 months after expiration to GFL at 76 Wentworth Court, Brampton, ON, L6T 5M7.
- Global Pharmaceutical CompaniescoreSteriMax partners with global and regional pharmaceutical companies to bring generic and branded medicines to market, improving patient access and addressing unmet medical needs. Includes both new chemical entities and reformulations of existing molecules.
- Healthcare Systems and Hospital GroupscoreStrong and longstanding relationships with National and Regional Hospital Group purchasing organizations, key provincial healthcare leadership, distributors, specialty pharmacies, and retail pharmacy banners across Canada.
- Global Export PartnersminorPartnerships with regional healthcare companies to deliver essential medicines beyond Canada, reinforcing healthcare systems in markets that depend on consistent supply.
- NovartiscoreIn 2004, SteriMax acquired five injectable products from Novartis, solidifying its market position as a provider of niche, small-volume sterile injectable products.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
SteriMax competitors and assessment
Company assessmentBroad incumbents
- Sandoz: Sandoz is the global leader in generic sterile injectable pharmaceuticals with a broad hospital injectable portfolio across therapeutic areas. It directly competes with SteriMax in generic sterile injectables, but at much larger global scale, serving the same hospital and pharmacy channels.
- Fresenius Kabi: Fresenius Kabi is a major global manufacturer of sterile injectable generics, infusion solutions, and clinical nutrition products. It overlaps with SteriMax's hospital injectable portfolio and was a previous employer of SteriMax's EVP Sales & Marketing, reflecting direct industry overlap.
- Hospira (Pfizer Injectables): Pfizer's hospital injectable business (formerly Hospira) is a global leader in sterile injectable pharmaceuticals. It directly competes with SteriMax in many of the same generic injectable molecules and supplies Canadian hospitals through similar distribution channels.
- Teva Pharmaceutical Industries: Teva is one of the largest generic pharmaceutical manufacturers globally with a substantial sterile injectable portfolio. It overlaps with SteriMax across generic injectables and serves similar hospital, pharmacy, and distribution channels in North America.
- Aurobindo Pharma: Aurobindo is a global generic pharmaceutical manufacturer with a growing sterile injectable portfolio serving North American markets. It overlaps with SteriMax in generic injectable therapeutic categories and competes in similar hospital channels.
- Dr. Reddy's Laboratories: Dr. Reddy's is a global pharmaceutical company with a substantial sterile injectable franchise in North America, including oncology and hospital injectables. It competes with SteriMax in many of the same molecules and customer segments.
Direct peers
- Hikma Pharmaceuticals: Hikma is a specialty generic injectable manufacturer with a strong North American hospital franchise. It directly competes with SteriMax in generic sterile injectables across similar therapeutic categories, including anti-infectives, cardiovascular, and oncology.
- Amphastar Pharmaceuticals: Amphastar is a US-based specialty pharmaceutical company focused on injectable and inhalation products, including niche sterile injectables. It is comparable to SteriMax in product mix (niche injectables), hospital customer focus, and specialty product positioning.
- Apotex Inc. Apotex is Canada's largest generic pharmaceutical manufacturer with a portfolio that includes sterile injectables and serves Canadian hospitals and pharmacies. It is a direct domestic peer to SteriMax, competing for hospital and GPO contracts in Canada.
Regional players
- Medicure Inc. Medicure is a Canadian specialty pharmaceutical company with branded hospital products including cardiovascular injectables. It shares SteriMax's Canadian market focus, hospital customer base, and branded/specialty product strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks1 record
Key highlights1 record
Customer concentration
SteriMax social profiles
Digital presenceSteriMax compliance and trust
Trust signalCompliance1 record
SteriMax financial estimates
Financial estimateRevenue estimate
Valuation estimate
SteriMax leadership team
Management profileNumber of profiles
Profiles8 records
SteriMax funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SteriMax M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SteriMax
What does SteriMax do?
SteriMax develops, manufactures, and distributes generic sterile injectable pharmaceuticals and branded specialty medicines for Canadian hospitals, pharmacies, and healthcare systems. The company offers over 50 products across therapeutic categories including anesthetics, anti-infectives, cardiovascular, critical care, electrolytes, hormones, and oncology, including proprietary ready-to-administer formats with 2D barcoding for medication safety.
Is SteriMax a public or private company?
SteriMax is a private company. It is classified as family owned and is currently operating.
When was SteriMax founded?
SteriMax was founded in 1994. It employs 101 to 250 people.
Where is SteriMax based?
SteriMax is headquartered in Oakville, Canada, in the North America region.
How does SteriMax make money?
Three revenue lines are on record. Generic Sterile Injectables are the primary driver. The others are branded Specialty Medicines and exceptional Importation (Tier 3).
Who are SteriMax's main competitors?
Broad incumbents on record are Sandoz, Fresenius Kabi, Hospira (Pfizer Injectables), Teva Pharmaceutical Industries, Aurobindo Pharma and Dr. Reddy's Laboratories. Direct peers are Hikma Pharmaceuticals, Amphastar Pharmaceuticals and Apotex Inc.. Medicure Inc. is listed as a regional player.
Does SteriMax have an API?
No public API is recorded for SteriMax.
What industry is SteriMax in?
SteriMax's product category is Generic Sterile Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIABAC, Sterile Injectable Generics, with a secondary code of HLAIABAL, Generic Hospital & Institutional Products. Its NAICS code is 325412 and its SIC code is 2834.